This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


Syndax Pharmaceuticals, Inc.

Drug Names(s): UCB-6352, UCB 6352

Description: UCB6352 is a high affinity monoclonal antibody targeting the colony stimulating factor 1 receptor (CSF-1R). CSF-1R is expressed on monocytes and macrophages and activated through its ligands, IL-34 and CSF-1.

Deal Structure: Syndax and UCB
In July 2016, Syndax entered into an exclusive worldwide license agreement with UCB for UCB6352, an IND-ready anti-CSF-1R monoclonal antibody, which is expected to begin clinical trials in 2016. Syndax will make a one-time upfront payment and will be responsible for development, manufacturing and global commercialization. UCB will receive milestones and tiered royalties on net sales.

Partners: UCB SA

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug